By employing network pharmacology strategies, Zheng et al. confirmed that HLJDD mainly exerts anti-AD effects by acting on multiple potential therapeutic targets, such as VEGFA, AKT1, TNF, YP53 and PTGS2 (Zheng R. et al., 2023). This evidence concerns the gene PTGS2 and Alzheimer disease.